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Abstract 
Rationale: Traumatic brain injury (TBI) leads to neurological impairment, with no 
satisfactory treatments available. Classical ketogenic diets (KD), which reduce reliance on 
carbohydrates and provide ketones as fuel, have neuroprotective potential, but their high fat 
content reduces compliance, and experimental evidence suggests they protect juvenile brain 
against TBI, but not adult brain, which would strongly limit their applicability in TBI.  
Methods: We designed a new-KD with a fat to carbohydrate plus protein ratio of 2:1, 
containing medium chain triglycerides (MCT), docosahexaenoic acid (DHA), low glycaemic 
index carbohydrates, fibres and the ketogenic amino acid leucine, and evaluated its 
neuroprotective potential in adult TBI. Adult male C57BL6 mice were injured by controlled 
cortical impact (CCI) and assessed for 70 days, during which they received a control diet or 
the new-KD.  
Results: The new-KD, that markedly increased plasma Beta-hydroxybutyrate (β-HB), 
significantly attenuated sensorimotor deficits and corrected spatial memory deficit. The lesion 
size, perilesional inflammation and oxidation were markedly reduced. Oligodendrocyte loss 
appeared to be significantly reduced. TBI activated the mTOR pathway and the new-KD 
enhanced this increase and increased histone acetylation and methylation.  
Conclusion: The behavioural improvement and tissue protection provide proof of principle 
that this new formulation has therapeutic potential in adult TBI. 
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Introduction 
Traumatic brain injury (TBI) is a leading cause of death and disability worldwide [1]. The 
primary injury leads to tissue disruption, loss of neuronal and non-neuronal cells, 
neuroinflammation, oxidative stress, and brain dysconnectivity [2]. These changes underlie 
the functional sensorimotor and cognitive deficits seen post-trauma. At present there is no 
satisfactory treatment and furthermore, TBI increases the risk of neurodegenerative diseases, 
such as dementia [3] and is also associated with the risk of developing post-traumatic epilepsy 
[4].  
In parallel with brain structure disruption, TBI leads to altered cerebral energy metabolism. 
Under normal conditions, glucose is the main energy-producing source in the brain. TBI leads 
to an acute glucose hypermetabolism [5], followed by a prolonged cerebral glucose 
hypometabolism. Under these conditions, the brain can switch to the use of an alternative fuel, 
such as ketone bodies (KB) [5]. KB, i.e. ß-hydroxybutyrate, acetoacetate and acetone, are 
synthesized from fatty acids in the liver. KBs can be produced under conditions of caloric 
restriction or during use of ketogenic diets (KDs). KDs are characterised by a high fat and low 
carbohydrate content, and their use leads to the development of a state of ketosis, i.e. increase 
in plasma and tissue KB levels [6]. The KD dietary concept was first developed in the 1920s 
as a therapy for epilepsy and has been in clinical use worldwide as a non-pharmacological 
treatment option for treatment-resistant epilepsy [7]. KD-based interventions are well-
established in pediatric epilepsy [8] but less so in adult epilepsy [9]. They have significant 
efficacy in reducing seizures, but these fat-rich diets have low palatability and can lead to 
adverse effects, such as tiredness, excessive thirst, kidney stones and constipation, which 
significantly reduce patient compliance [10]. 
Apart from epilepsy, KD interventions have been shown to have neuroprotective potential in a 
variety of other neurological indications [9, 11, 12]. However, in TBI the experimental 
evidence generated in rodents so far with classical KD (with ratios of fat to protein and 
carbohydrate of 4:1 or higher), suggests that the neuroprotective effect of such an intervention 
would be limited to the protection of the juvenile brain only [13-15].  
In the present study, we tested a new-KD formulation in an experimental model of TBI, the 
controlled cortical impact (CCI) model, in adult mice. The new-KD formulation contained 
medium-chain triglycerides (MCT) and also the long-chain polyunsaturated fatty acid 
docosahexaenoic acid (DHA), which has been shown to have intrinsic neuroprotective 
properties in TBI [16, 17]. It also contained low glycaemic index carbohydrates, fibres, and 
the ketogenic amino acid leucine, with a resulting overall ratio of fat to protein and 
carbohydrate of 2:1. We hypothesised that this composition would increase the 
neuroprotective effect of the diet, while maintaining its ketogenic potential and also 
increasing its palatability and reducing the adverse effects of the classical KD for more 
compliant use in patients. As the energy demise after TBI occurs very rapidly, we fed the 
animals this diet immediately after injury and maintained them on it for 70 days, while 
monitoring their recovery. We show that this new-KD formulation improves several aspects 
of neurological outcome and significantly counters the tissue damage and the increased 
inflammation and oxidation triggered by injury, and thus we present the first experimental 
evidence that a KD designed this way could confer neuroprotection in adult TBI. 
 
Materials and Methods 
Animals 
A total of 30 adult, 10-12 week-old male C57BL/6 mice, weighing 22-27 g (Charles River 
Laboratories, Margate, UK), were housed in groups of five, maintained the same throughout 
the study, in Individually Ventilated Cage (IVC; Allentown Europe, UK), in a 12 h light-dark 
cycle, with controlled room temperature (21 ± 1 °C) and relative humidity (40-60 %) and with 
diet and water ad libitum. Health screens provided by the vendor indicated that animals were 
free of known pathogens in accordance with FELASA guidelines. A 7-day acclimatization 
phase occurred prior to the study. Food intake and body weight were monitored daily. All 
animal procedures were carried out under a Project Licence approved by the Animal Welfare 
and Ethical Review Body, at Queen Mary University of London and the UK Home Office, in 
accordance with the EU Directive 2010/63/EUT 
Controlled cortical impact model 
A controlled cortical impact (CCI) TBI model was used, as previously [18]. After 1-week 
acclimatisation, mice were anaesthetized using ketamine (50 mg/kg) and medetomidine (0.5 
mg/kg; i.p.). Mice were placed in a stereotaxic frame and a midline longitudinal incision was 
performed to expose the skull. A right lateral craniotomy was carried out using a pneumatic 
drill, 2.0 mm behind bregma and 2.5 mm lateral to the midline. CCI injury was induced using 
the following settings: a 3 mm impactor tip with a speed of 3 m/s, a depth of 2.2 mm and a 
dwell time of 100 ms, applied using the PCI3000 Precision Cortical Impactor™ (Hatteras 
Instruments, Inc., US). A control group underwent craniotomy only. After injury, the skull 
flap was placed back, to allow for expansion, and the skin was sutured. Mice were allowed to 
recover in an incubator (37°C) until fully awake and active. Buprenorphine (0.05 mg/kg, s.c.) 
was used in all animals pre-operatively for pre-emptive analgesia and post-operatively every 
12 h for 3 days post-surgery. 
Dietary supplementation 
Following CCI, mice were randomized into two groups and fed with a control diet (‘CCI-
Control’; n=10) or with the new preparation of a ketogenic diet (KD) (‘CCI-KD’; n=10) for 
70 days (detailed composition in Table 1). The craniotomy group were fed with control diet 
(craniotomy; n=10). The diets were formulated by Danone Nutricia Research (Utrecht, The 
Netherlands) and manufactured by Ssniff (Soest, Germany). The caloric value of the control 
and new diet were 377 kcal/100g and 626 kcal/100g, respectively. The comparison between 
this diet and various other diets with variable ratios fat : carbohydrate and protein is shown in 
Table S1. Diets were stored at -20°C to prevent lipid peroxidation, and fresh diet was given 
daily. No significant differences were seen in the body weight (Figure S1A) and food intake 
curves between the various experimental groups, throughout the study. All the behavioural 
work (the primary study endpoint) and tissue analysis, was assessed in “blind”, with the 
researcher unaware of the treatment, in accordance with the ARRIVE guidelines [19]. 
Experimental design and Behavioural testing 
The testing carried out on various days post-injury (dpi) is summarised in Figure S1B. Sample 
size was estimated using power analysis (https://eda.nc3rs.org.uk/eda/) for pairwise post-hoc 
comparisons after ANOVA, at a statistical power of 90%, with a significance level α < 0.05.   
Modified Neurological Severity Score (mNSS) 
The mNSS was used as previously [20, 21], using a scoring based on the ability to perform 
ten tasks that evaluate motor ability, balance and alertness (Figure S2A). For each 
performance criterion, the animal can receive a score of 0 (no deficit) or 1 (deficit observed), 
on occasions 0-3 for increasing severity of deficit. The first mNSS was obtained 24 h after 
TBI. During the first week, testing was performed every other day, then once a week, until the 
end of the experiment.  
Rotarod 
The Rotarod test (Ugo Basile, France; 3 cm diameter) was used for the evaluation of motor 
coordination and balance. Prior to surgery, mice were trained on the Rotarod for three 
consecutive days. The first two trials were 60 s each, at 3 rpm, followed by a single trial at 
accelerating speed (3 to 20 rpm over 300 s, with intervals of at least 25 min rest). The rest of 
the training days consisted of one trial at 3 rpm followed by two accelerating trials. The 
latency to fall from the Rotarod was recorded. The average of all accelerating phase scores 
was considered as the baseline (pre-injury score). Mice were tested during day 1-3 post-
injury, in three trials a day, using the accelerating mode. 
Morris Water Maze 
The Morris water maze test (MWM) was used to assess memory associated with spatial 
learning between days 13-18 post-CCI. A 100 cm diameter pool filled with opaque water at 
23°C was placed inside a white tent, ensuring light uniformity, with 4 visible cues hung 10 cm 
from the pool walls and a 11 cm diameter Plexiglas resting platform submerged 0.5 cm below 
water level. Swimming performance (e.g. path, distance, speed and latency) was tracked using 
software (ANYmaze, Smart, Bioseb, France). A learning period of 5 consecutive days (days 
13-17 post-injury) and a probe trial on day 6 (day 18 post-injury) were used. During the 
learning period, each mouse was subjected to 4 trials a day, in the pool divided into 4 virtual 
quadrants. The position of the platform was constant throughout the training session, while 
the starting position on each of the 4 training trials was changed. If a mouse did not find the 
platform within 60 s, it was guided to it. After reaching the platform, mice were allowed to 
stay there for 15 s. During the probe trial, mice were allowed to swim for 60 s in the absence 
of the platform, and the time it took to first enter the quadrant that had previously hosted the 
platform, was measured. 
BrdU injections 
From day 63 post-injury or craniotomy, and for 7 sequential days, animals received i.p. 
injections of 5-bromo-2-deoxyuridine (BrdU; 50 mg/kg, twice a day), to assess cell 
proliferation.  
Histology and immunohistochemistry 
At day 70 post-TBI, 5 animals from each group were deeply anaesthetized with sodium 
pentobarbital (50 mg/kg, i.p.; Sagatal, Rhone Merieux, Harlow, UK), and received a 
transcardiac perfusion with phosphate-buffered saline (PBS; 0.01 M, pH 7.4), followed by 4% 
paraformaldehyde (PFA) in phosphate buffer (0.1 M, pH 7.4, 4°C). The brains were dissected 
out, fixed and paraffin-blocked for histology and immunohistochemistry (IHC) analyses. 7 
μm sections were deparaffinised and hydrated (xylene and ethanol). Sections were subjected 
to antigen retrieval (10 mM citrate buffer, pH 6.0, 30 min at 80°C), then cooled at room 
temperature. The tissue was blocked with 5% normal donkey serum in 0.2% Triton X-100 in 
PBS for an hour, followed by three PBS washes. The primary antibodies used were (overnight 
incubation): rat anti-BrdU (1:200; Acris Antibodies GmbH, Cat# SM1667PS), rabbit anti-
glial fibrillary acidic protein (GFAP) (1:800; Dako, Cat# Z0334), goat anti-Iba-1(1:800; 
Wako, Cat# 019-19741) and rabbit anti–translocator protein (TSPO) (1:100; Abcam, Cat# 
ab109497), mouse anti- APC (1:50; Millipore, Cat# OP80), 8-OHG (1:200; QED bioscience, 
CAT# 12501clone 15A3).  The secondary antibodies used were labelled with Alexa 488 or 
Alexa 555 (Molecular Probes, Leiden, The Netherlands; 1:200), and Hoechst 33342 stain 
(Sigma, UK; 1 μg/ml PBS) was used to visualize nuclei. Slides were mounted and cover-
slipped using Vectashield fluorescent mounting medium (H-1000; Vector Laboratories, 
Burlingame, CA). For the analysis of NDUFS4 positive cells, we used the EnVision™+ 
System, HRP (DAB) with rabbit primary antibodies Kit (Dako, CAT #K4011), Rabbit anti-
NDUFS4 (1:2000; Abcam, CAT# ab137064). The antibody was diluted using diluent with 
background reducing components (Dako, CAT #S3022). 
For calculation of the lesion size, sections of 7 µm, 200 μm apart and spanning the entire 
rostro-caudal extent of the injured cortex were stained with haematoxylin and eosin (H&E). 
The lesion size was measured with ImageJ software (NIH, Bethesda, MD, USA) and 
calculated using the equation: the contralateral (non-lesioned) hemisphere size minus the 
injured hemisphere size and divided by the contralateral hemisphere size (Swanson et al, 
1990). The results are expressed as a percentage of hemispheric tissue. 
Image capture analysis and processing 
Four sections per animal were stained, per antibody. At least 24 fields/section were captured 
peri-lesionally (immediate area around the lesion). Images were viewed at ×40 and 
photographed using a Zeiss Axioskop 2 microscope with a Hamamatsu camera (C4742-95). 
Analyses were carried out by thresholding and then superimposed on nuclei, for co-
localization using a dedicated script (JVP AutoColourCellCountsRev) in ImageJ (ImageJ 
1.50i, NIH, Bethesda, Maryland). Quantification of microglia morphology was carried out 
using cell size in ImageJ (minimum 20 cells per animal). The soma perimeter was measured 
excluding the processes. A Zeiss LSM 710 confocal microscope was used for further 
characterization (ZENlite software; Zeiss, Cambridge, UK). Figures were prepared using 
Illustrator software (Adobe Illustrator CS6).  
Brain tissue preparations 
Brain tissue from 5 animals per group were used for western blot analysis, phospholipid 
analysis and the H3 Methylation/Acetylation assay. At day 70 post-TBI, animals were deeply 
anaesthetized with sodium pentobarbital (50 mg/kg, i.p.; Sagatal, Rhone Merieux, Harlow, 
UK), and decapitated. Brains, including the cerebellum, were removed and dissected using a 
brain matrix (as shown in Figure S2C). The contralateral and ipsilateral hemispheres were 
separated. Tissue was snap frozen and stored at -80° C.   
Western blot analysis 
A cube of the right hemisphere around the lesion was dissected and sonicated in RIPA lysis buffer 
(Sigma-Aldrich) complete with Protease Inhibitor Cocktail (Sigma-Aldrich), then centrifuged (10,000 
x  g, 10 min, 4°C) and the supernatant was taken. Protein concentrations were determined using the 
Bradford assay. Equal amounts of protein (50 µg) were mixed with NuPAGE® LDS sample buffer 
(Thermo Fisher Scientific) and dithiothreitol (DTT) and boiled (95°C, 10 min), then separated using 
Mini-Protean TGX Gels, 10% (Biorad, UK) and electro-transferred onto polyvinylidene difluoride 
membranes (Biotrace). Membranes were blocked in 5% non-fat dry milk in Tris-buffered saline (pH 
7.4), with 0.1% Tween-20 (Tris-buffered saline–Tween) for 1 h at room temperature. The primary 
antibodies used were: total The mammalian target of rapamycin (mTOR Rabbit, 1:2,000, Cell 
Signalling product# 2983, Kit Cat# 9862), p-mTOR (Ser2448; Rabbit 1:2000; Cell Signalling 
product# 5536, Kit Cat# 9862), phosphorylated p70S6 Kinase (Ser371; Rabbit; 1:1000; Cell 
Signalling product# 9208, Kit Cat# 9862), all diluted in 5% bovine serum albumin solution, and 
membranes were incubated overnight at 4°C. The primary antibody was removed and blots were 
washed in Tris-buffered saline–Tween and incubated (1 h, room temperature) in horseradish 
peroxidase-conjugated secondary antibodies (1:10,000; Jackson ImmunoResearch Labs Cat# 323-005-
021). Reactive proteins were visualized using enhanced chemiluminescence (VWR International). 
Optical density was determined using ImageJ software (NIH, Bethesda, Maryland). Membranes were 
also incubated with a mouse vinculin monoclonal antibody (1:4,000; clone VIN-11-5, Sigma-Aldrich 
Cat# V4505), for normalisation. Protein level was expressed as relative optical density, i.e. the optical 
density of the band revealed by the primary antibody, divided by the optical density of vinculin in the 
same lane. 
Phospholipid (PL) analysis 
PL analysis was carried out as previously described [22]. Lipids were extracted from the 
cerebellum using the method of Folch and colleagues [23], with 0.01% (w/v) 2,6-di-tert-butyl-
p-cresol (butylated hydroxytoluene)  as antioxidant. Neutral and acidic PLs were isolated 
from the lipid extract by solid-phase extraction using Isolute® bonded phase aminopropyl 
columns (Kinesis Health Technologies, Dublin, UK). The various PL, i.e. 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylinositol (PI) and sphingomyelin (SM) were separated by thin-layer 
chromatography, and the phosphate content measured. The results were normalized to 100 mg 
wet tissue weight. 
H3 Methylation/Acetylation Assay 
Histones were extracted from the contralateral hemisphere and were homogenized using the 
EpiQuik total histone extraction kit (# OP-0006, EpiGentek, Farmingdale, NY, USA) 
according to manufacturer’s directions. EpiQuik™ Global methylation levels of H3K9 
(EpiQuikTM Global Histone H3K9 Methylation Assay Kit; CAT# P-3018-96; Epigentek, NY, 
USA) and global acetyl Histone H3-K9 levels (EpiQuik™ Global Acetyl Histone H3-K9 
Quantification Kit CAT# P-4010-96; Epigentek, NY, USA) were determined using a 
colorimetric ELISA assay as per manufacturer’s protocols. Absorbance was measured using a 
spectrophotometer (450 nm wavelength) with a CLARIOstar® microplate reader and MARS 
software, and the acetylation and methylation calculated accordingly, with reference to the 
standard. 
Beta-hydroxybutyrate (β-HB) analysis in plasma  
Blood samples were collected (n=10/group) through intracardiac sampling, plasma was 
prepared by centrifugation (12,000 x g for 5 min) and samples were separated into aliquots. ß-
HB was analysed in plasma using the Beta-Hydroxybutyrate Assay Kit (#MAK041; Sigma 
Aldrich, MO, USA). The assay was performed according to the manufacturer’s instructions, 
with all samples in duplicate. To avoid the presence of interfering substances in the plasma 
samples, all proteins were filtered out (deproteinized), using a 10 kDa mw cut-off spin filter. 
A β-HB standard curve was generated in parallel.  
Data analysis 
Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, San Diego, 
USA). Data was expressed as mean ± sd. Parametric data was analysed using unpaired, Two-
tailed t-test, one-way ANOVA or two-way ANOVA, following Tukey’s multiple 
comparisons, except when otherwise stated. The level of significance was set to p<0.05. All 
analysis was carried out blind to experimental condition. 
Results  
KD supplementation improves sensorimotor impairment after CCI 
Following TBI patients suffer from heterogeneous and complex neurological sensorimotor 
deficits such as lack of muscle coordination, impaired balance, muscle weakness, 
paresis/paralysis, postural imbalance and gait disturbance. Sensorimotor impairment was 
assessed with the mNSS and Rotarod tests. TBI led to early significant deficit in the mNSS 
and all groups showed a gradual decrease in TBI-induced impairment over 70 days. However, 
a significant improvement was observed in CCI-KD animals already after 3 days post-injury, 
compared to the CCI-Control group. This difference in mNSS was maintained until the end of 
the study (Two-way ANOVA; p < 0.0001, F (2, 28) = 247.8; Figure 1A). The craniotomy 
control animals showed only a transient impairment.  
The Rotarod revealed better performance in the KD-treated animals compared with the 
control diet group at all three time points after injury (Two-Way ANOVA; p < 0.0001, F (2, 
27) = 37.46; Figure 1B). The fall latency was significantly higher in the CCI-KD animals, 
compared to CCI-Control animals. The craniotomy-control group showed minimal 
impairment in coordination and balance. 
KD improves spatial memory deficits in the MWM after CCI 
TBI leads to cognitive deficits in areas such as learning, memory and attention. The 
hippocampus plays a key role in the acquisition and processing of new memories. A 
significant hippocampal lesion was apparent in control- CCI animals. The spatial memory was 
assessed using the MWM. No significant differences were seen between groups during the 
learning/acquisition phase (Figure S2B). CCI led to significant impairment in the probe trial; 
the new-KD fed animals showed significantly improved performance in the probe trial 
compared to the injured animals fed the control diet. (One-Way ANOVA; p = 0.001, F (2, 29) 
= 8.262; Figure 1C).  
KD significantly elevates the plasma levels of ß-hydroxybutyrate after CCI 
It is well-established that classical KDs are associated with an induction of ketosis, which can 
be assessed by measuring the β-HB plasma levels. After 70 days of exposure to the diet, a 
significantly higher plasma β-HB level was detected in the CCI-KD group compared to the 
CCI-Control animals. Craniotomy controls did not show detectable levels of plasma β-HB in 
plasma (Unpaired t-test; p =0.0009, F (8, 2) = 5.709; Figure 2A). 
KD supplemented animals show a significant reduction in lesion size, a decrease in an 
oxidation marker and changes in brain PL levels 
TBI is associated with rapid loss of grey and white matter that contributes to the overall brain 
volume loss seen post-traumatically [24]. TBI-induced cell loss is associated with necrosis 
and apoptosis, followed by the removal of cell debris by microglia and macrophages. Analysis 
of the lesion size after 70 dpi showed a significant loss of tissue, with almost total loss of the 
ipsilateral hippocampus. The new-KD-fed mice had a significantly decreased lesion size 
(Unpaired t-test; p =0.01, F (5, 4) = 2.161; Figure 2B).  
TBI leads to the generation of oxidative stress [25, 26] which we assessed using 8-
hydroxyguanosine (8-OHG), a nucleic acid oxidation marker. TBI led to a high level of 
oxidative damage in the CCI-Control diet group compared to the craniotomy group, and there 
was a significant reduction in the new-KD-fed animals (One-Way ANOVA; p =0.0001, F (3, 
15) = 227.8; Figure 2C; a-d)
CCI in mice is associated with a decrease in brain PL levels [24]. The analysis of the PL in 
the cerebellum showed that PC and PE levels decreased significantly following the injury 
compared to the craniotomy group, whereas in the group fed with KD, the loss in PL was 
reduced. Tissue PC levels were reduced by 20% in injured animals on the control diet vs. 
craniotomy controls, and this was reduced to 12% in the new-KD group compared with 
craniotomy controls. PE levels decreased by 20% in the injured animals on the control diet vs. 
craniotomy-only, while after the new-KD the difference vs. craniotomy controls was only 
8.5%. (Two-way ANOVA, p < 0.0001; F (2, 26) = 43.53; Figure 3A). Injury also led to 
decreases in PI, PS and SPH (-19%, -15% and -19% vs. craniotomy-controls, respectively), 
but the new-KD did not alter these changes (Two-way ANOVA, P<0.0001 F (2, 39) = 15.12; 
Figure 3B). 
KD supplementation leads to a decrease in microglia/macrophage activation but does 
not alter the astrocyte response post-injury 
TBI is followed by intense activation of a microglia and macrophage response. This activation 
is reflected in morphological changes and is one of the hallmark of TBI pathophysiology [27]. 
Microglia, the resident brain immune cells, undergo a transition from a resting state- ramified 
morphology to an amoeboid morphology, which reflects the activated state. In the last decade, 
it has been shown in human imaging studies that these cells still show signs of activation 
many years after injury [28].  This long-lasting response has also been described in mice and 
non-human primates [29] and is incompletely understood. We used the classic 
microglia/macrophage marker, Iba-1, and the translocator protein (TSPO) marker that has 
been the used extensively for imaging microglia activation state [30]. TSPO is expressed in 
the outer mitochondrial membrane and is present in low concentrations in the healthy brain; it 
is significantly upregulated in response to brain injury.  
The percentage of Iba-1 positive cells out of total DAPI, around the lesion was higher in the 
CCI-Control diet group compared to the CCI-KD and craniotomy groups. (One-Way 
ANOVA; p = 0.002, F (2, 12) = 10.15; Figure 4A, b, f, j). Moreover, the new-KD fed mice 
showed an overall decrease in the percentage of TSPO-positive cells compared to control diet-
treated CCI animals (One-Way ANOVA; p < 0.0001, F (2, 12) = 119.3; Figure 4B, c, g, k). 
The co-staining for Iba-1 and TSPO showed a significantly lower percentage of double-
stained cells in the CCI-KD group compared to the CCI-Control group (One-Way ANOVA; p 
< 0.0001, F (2, 12) = 68.56; Figure 4C, d, h, l). Next, we explored the microglia/macrophage 
morphological differences between the CCI-Control diet group (predominantly amoeboid), 
the CCI-KD group (less amoeboid) and craniotomy-control group (predominantly ramified) 
by measuring cell size. Microglia cells in the CCI-Control diet group were significantly bigger 
compared with the CCI-KD diet group (Mann Whitney test p= 0.008; Figure 4D).  
In response to TBI, astrocytes become reactive [31]. The astrogliotic reactivity is reflected in 
both proliferation and cell hypertrophy. After a traumatic injury, astrocytes can exert both 
harmful and protective effects, e.g. ablation of astrocytes soon after brain injury in mice, led 
to a poorer outcome, suggesting an important protective role of astrocytes after injury [32, 
33]. 
CCI led to an increase in the percentage of the positive astrocyte marker- glial fibrillary acidic 
protein (GFAP), out of total DAPI - around the lesion border, with no differences between the 
control diet and the new-KD diet groups (One-Way ANOVA; p < 0.0001, F (2, 10) = 118.8; 
Figure 5A, b, f, j). Additionally, in both diets, after TBI, there was an increase in newly-
formed astrocytes, i.e. cells double-labelled with GFAP and BrdU, at 70 dpi (One-Way 
ANOVA; p = 0.005, F (2, 10) = 9.652; Figure 5C, d, h, l). 
KD supplementation modulates cell proliferation after CCI 
TBI is associated with an increase in cell proliferation, including an induction of neurogenesis 
[34] [35], processes which are interpreted as repair mechanisms. New-born cells are detected 
not only in the neurogenic areas of the brain (such as the subgranular zone of the dentate 
gyrus or the subventricular zone of the lateral ventricles), but also in the perilesional area, and 
in contralateral hemisphere regions such as the hippocampus. The analysis of proliferating 
cells after CCI around the lesion, showed a significantly higher percentage of BrdU-positive 
cells compared to the craniotomy group. The treatment with KD led to a noticeably increased 
perilesional cell proliferation (One-way ANOVA; p < 0.0001, F (2, 12) = 23.71; Figure 5B, c, 
g, k).  
KD supplementation leads to the protection of oligodendrocytes after CCI 
Oligodendrocytes are responsible for producing myelin and maintaining myelinated fibres in 
the brain. TBI alters the response of both mature oligodendrocytes and immature proliferative 
oligodendrocytes [36]. We show that the CCI injury led to a significant reduction in the 
percentage of oligodendrocytes, labelled with adenomatous polyposis coli (APC) out of total 
DAPI, perilesionally. This injury-induced decrease was significantly affected by the new-KD 
(One-Way ANOVA; p = 0.005, F (2, 12) = 8.563; Figure 6A, b, f, j). In addition, dual staining 
of APC and BrdU showed a higher percentage of double-stained APC/BrdU cells in the CCI-
KD group compared with the two other groups (CCI-Control 2.4±0.35; CCI-KD 4.1±0.38; 
Craniotomy 1.4±0.2; One way ANOVA; p = 0.002, F (2, 12) = 18.15; Figure 6B, d, h, l).  
KD modulates mTOR signalling and alters the mitochondrial marker NDUFS4 levels 
after CCI  
The mammalian target of rapamycin (mTOR) is a protein kinase that integrates energy, 
nutrient and growth factor signals to regulate various cellular functions, when activated. It is 
part of two distinct multi-protein complexes, mTORC1 and mTORC2. The activation of 
mTOR has been associated with repair mechanisms after neural injury [37, 38]. One of the 
downstream signalling effectors in the mTORC1 pathway is p70S6k (ribosomal protein S6 
kinase beta-1). There is an increase in the levels of phosphorylated mTOR (p-mTOR) in the 
injured tissue and the new-KD further amplified this response to injury. Thus, the ratio of p-
mTOR/mTOR, at 70 days after injury, significantly increased in the CCI-KD group compared 
to both CCI-control and craniotomy groups (1.34±0.08 vs. 0.75±0.07 and 0.34±0.05 
respectively; One-Way ANOVA ***p<0.0001, F(2,12)=51.26; Figure 7C). The new-KD also 
increased the level of the mTORC1 downstream effector p70S6k in its phosphorylated form at 
70 days post injury compared to the CCI-Control and craniotomy groups (p-mTOR: One-Way 
ANOVA; p = 0.001, F (2, 11) = 37.44; Figure 7A, B and p70S6k: One-Way ANOVA; p = 
0.001, F (2, 7) = 44.72; Figure 7D).  
TBI induces acutely a significant mitochondrial dysfunction[39]. The protein NADH 
dehydrogenase [ubiquinone] iron-sulfur protein 4 (NDUFS4) is an accessory subunit of the 
mitochondrial membrane respiratory chain NADH dehydrogenase (complex I). It is a 
membrane protein located in the inner mitochondrial membrane and it is part of the 
mitochondrial respiratory chain that plays a vital role in cellular ATP production. At 70 days 
post-injury we detected a marked increase in NDUFS4, and the levels of this mitochondrial 
marker NDUFS4 in the perilesional area were reduced in the injured mice receiving the new-
KD (One-Way ANOVA; p = 0.0006, F (2, 9) = 19.18; Figure 8A). 
KD modulates H3K9 methylation and acetylation 
In the last decade, evidence has been accumulating that ketones can induce epigenetic 
modifications, such as increased histone acetylation and DNA methylation[40]. A strong 
effect of the new-KD was observed on both histone H3K9 methylation and acetylation 
compared with the CCI-Control and craniotomy groups (One-Way ANOVA; p = 0.0004, F (3, 
15) = 11.33; Figure 8B and One-Way ANOVA; p < 0.0001, F (3, 15) = 20.71; Figure 8C 
respectively). 
Discussion and conclusion 
In this study, we carried out a TBI in adult mice using the CCI model - which was previously 
shown to be insensitive in adult animals to ketogenic dietary intervention [13] and fed the 
animals a new-KD for 70 days post-injury, while assessing the neurological outcome. The 
CCI model involved replacing of the bone flap and allowing expansion, therefore the 
observations presented with this new diet can be interpreted as reflecting a clinical situation 
where there is control of the acute rise in intracranial pressure following a severe injury.  We 
also examined the brain tissue at the end of the experiment, for signs of neuroprotection. We 
present evidence that a new ketogenic formulation given immediately post TBI in adult 
animals can lead to functional neurological benefits and can reduce the injury impact on brain 
tissue. This new preparation has a lower fat to carbohydrate and protein ratio, i.e. a ratio of 
2:1 vs. a ratio of 4:1, which is characteristic of classical KD formulations, and includes 
medium chain triglycerides (MCT), docosahexaenoic acid (DHA) and leucine. It is also 
higher in protein, fibres and carbohydrates with low glycaemic index, compared with the 
classic KD. 
Intervention with this novel KD formulation reduced sensorimotor impairment, including 
coordination and balance, and improved spatial memory recovery after injury. Tissue loss 
post-injury is linked to the sensorimotor and cognitive deficits seen after injury [41]. The 
brain lesion size was significantly decreased in the new-KD group compared to the injured 
animals on control diet, and the PL loss in tissue following injury was also attenuated.  
TBI initiates a series of neurochemical events that compromise cerebral energy metabolism. 
This metabolic disruption requires high cellular energy to reinstate homeostasis. TBI leads to 
a transient “hyperglycolysis” phase (possibly associated with the acute post-injury increase in 
hypoxia-inducible factor 1-alpha [42]), followed by a prolonged period of metabolic 
depression, during which glucose utilisation drops dramatically. Although glucose serves as 
the main metabolic substrate for neurons, it has been shown that other energy-producing 
substrates, such as lactate and pyruvate, might be utilized by neurons to sustain their activity 
[15]. In addition to glucose metabolism, all cell types in the brain are capable to metabolise 
ketone bodies when present, and ketones are capable of fulfilling the energy requirements of 
the brain. Ketosis, reflected in elevated β-HB plasma levels, can be achieved by following a 
high-fat, low-carbohydrate classical KD that acts as a provider of alternative substrates for 
cerebral energy metabolism [6]. We show here that the β-HB plasma levels were significantly 
higher in the injured group fed with the new-KD, emphasising the fact that this formulation 
can lead to a state of ketosis, although the ketogenic ratio is lower than in the classical KD. 
The β-HB level we measured is in the range reported in previous studies with KD 
formulations in rats and mice [43-45]. 
The new-KD modified the neuroinflammation reaction post-injury, i.e. it reduced activated 
microglia peri-lesionally. Numerous studies have reported that post-injury changes in the 
microglia functional state are associated with the de novo expression of the mitochondrial 
translocator protein (TSPO). Post-TBI, there is an increase in TSPO levels [46, 47]. Here we 
show that injured animals fed with the new-KD had a significantly reduced TSPO expression 
in Iba-1 expressing cells compared with the injured animals fed with a control diet, at 70 days 
post-CCI.  
One other component of the glial response after TBI is represented by astrocytic activation. 
Astrocytes respond to mechanical strain and to the ATP released from injured cells at the 
injury site, which triggers astrocyte activation and recruits them to the site of injury. In 
response to a focal injury, reactive astrocytes form a scar border that isolates the damaged and 
inflamed tissue from the healthy tissue [48-50]. These scar borders are comprised almost 
entirely of newly proliferated astrocytes, which may subsequently contribute to tissue 
repair/regeneration [33, 51]. The present study indicates a strong astrocytic activation at more 
than 2 months after injury, as reflected by the GFAP marker, and also shows an increase in 
the numbers of newly-born astrocytes even at this late time post-injury, but with no 
differences between the control diet and the new-KD treated groups. 
TBI triggers loss of oligodendrocytes and demyelination, and there is a relationship between 
white matter loss and post-traumatic cognitive impairment [52, 53]. The current findings 
confirm the oligodendrocyte vulnerability after traumatic injury and indicate a protection of 
oligodendrocytes and also an increase in the newly formed oligodendrocyte pool along the 
lesion border, by the new-KD. As previously shown, CCI leads to a detectable decrease in PL 
species at this time point after injury [54].  The new-KD reduced the decrease in PC and PE, 
but, overall, the impact on PL loss in tissue was not as marked as the impact of a dietary 
supplementation with a combination of brain phospholipid precursors [54]. 
Studies on KD have shown that these fat-rich and carbohydrate-poor diets can induce 
epigenetic alterations, and it is interesting to note that epigenetic changes such as increased 
histone acetylation have been associated with improved learning and memory, while 
decreased acetylation is associated with cognitive impairment such as that seen during ageing 
[55, 56]. Gao and colleagues [57] have reported decreases in histone acetylation and 
methylation after TBI in the immature brain. Our new-KD induced a marked increase in 
histone acetylation and in histone methylation, therefore it could be suggested that this 
epigenetic modulatory effect might be beneficial post-TBI. 
Mitochondrial dysfunction is an early event post-trauma, and is a critical determinant of 
energy failure and cellular demise [58]. Mitochondria disruption is also a key link to increased 
oxidative stress [59], which appears to be reduced by the new-KD in the injured CCI tissue. 
Interestingly, our results show that injury leads to an increase in the tissue expression of the 
mitochondrial marker NDUFS4, and the new-KD significantly dampened this increase. The 
knockout of NDUFS4 in the heart has been shown to be protective in reperfusion injury 
following heart ischaemia [60]. Furthermore, it has been shown that the activation state of 
mitochondrial complex I is linked to reperfusion injury and oxidative stress post-ischaemia 
[61]. An improved understanding of the impact of the new-KD on brain mitochondria at this 
time after injury and a comprehensive interpretation of these first observations on the complex 
I marker, would be greatly aided by functional measures on fresh mitochondria isolated from 
the injured tissue, and a characterization of the transitions between conformational states 
(active vs. de-active and catalytically dormant) of complex I, as reported in recent studies in a 
murine model of immature hypoxia-ischaemia encephalopathy [62]. 
One of the changes reported in studies with KD in the context of epilepsy is an inhibition of 
mTOR [63], a signalling pathway whose activation is linked to epileptogenesis. It has been 
suggested that this inhibitory effect may be linked to the impact of KD on growth and also its 
anticonvulsant properties. It has been shown that TBI leads to a fast activation of mTORC1, 
and suppression of this initial activation may be beneficial [64]. We show that CCI in mice 
led in the long-term to an activation of mTOR (as reflected in the increase in p-mTOR), and 
this was enhanced by the new-KD, after 70 days of exposure to this diet. This enhancement in 
signalling was supported by the observed increase in phosphorylated p70S6k. It is tempting to 
suggest that this effect, which is reported for the first time after traumatic central nervous 
system injury, may be linked to beneficial effects of mTOR activation on compensatory brain 
plasticity post-injury and recovery of cognitive function [65, 66]; effects which are thus 
clearly opposite to the deleterious impact of mTOR activation in the acute phase. Although 
the new protein synthesis which would be involved in endogenous attempts to restore brain 
connectivity may not be exclusively under the control of mTOR (in particular mTORC1), this 
signalling pathway may still make a significant contribution to the reduction of the lesion and 
the inherent brain circuit remodelling involved in improved neurological performance. 
Interestingly, an increase in mTOR activation has also been reported after chronic exposure to 
a KD treatment which induced neuroprotection in a model of optic neuropathy [67]. In the 
present study, it is likely that the addition of leucine to the new-KD may have contributed to 
this effect. It would be interesting to assess in future studies whether the early post-injury 
effect of the new diet is to inhibit mTOR, whereas in time, the effect becomes opposite, and 
leads to stimulation of mTOR, which supports neurorepair. 
Overall, we show evidence in the present study that it is possible to characterize significant 
neuroprotective properties of a KD following TBI in an adult brain, using a new-KD 
formulation with a fat to carbohydrate and protein ratio which is also likely to be associated 
with an improved tolerability, and also enriched in omega-3 fatty acids, in particular, DHA, 
which has been shown to have intrinsic neuroprotective value in TBI. With reference to the 
DHA diet content of our new diet (1430 mg/100 g diet), it is interesting to note that Pu and 
collaborators [68] administered for 35 days a diet enriched in fish oil (4000 mg fish oil/100 g 
diet, containing  DHA and eicosapentaenoic acid (EPA);  EPA:DHA ratio of 2.6) following 
CCI in mice, and reported improvement in tissue protection and in functional outcome after 
injury.  As our first exploratory study was focused on the proof of principle for the whole diet,  
it is not possible to establish which diet component made the most critical contribution to the 
benefits seen on various endpoints, and this will need to be addressed with priority in future 
studies, to refine further the composition of the diet and better understand mechanistically its 
mode of action.  Future studies could help assess whether the beneficial long-term effects of 
the new diet are supported by very early neuroprotective mechanisms triggered in the first 
hours or day post-injury by the diet. This is the first evidence which suggests that a KD 
approach could be used in human adult TBI, expanding the range of potential clinical uses of 
this dietary KD principle [69] in an indication where there is a need to move away from 
glucose as a fuel and also avoid hyperglycaemia [70], which is a modifiable risk factor 
contributing to poor outcome in TBI [71]. How this dietary paradigm could be implemented 
post-trauma in the context of human TBI, and the exact dietary regime parameters, i.e. 
optimum onset and duration of the intervention, remain to be clarified in further studies.  
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Diet compositions Control New KD
g / 100g diet g / 100g diet
Soy oil 1.90
Corn oil 2.20
Coconut oil 0.90 4.40
Tuna oil 5.70
Palm oil 39.90
Rapeseed oil 5.70
MCT oil 1.30
Caseine (85%) 14.00 18.70
L-Cystine 0.18 0.30
L-Leucine 1.90
Cornstarch, pre-gelatinized 45.59
Maltodextrin, 10 DE 15.50
Sucrose 10.00
Galactose 1.50
Isomaltulose 2.72
Cellulose  powder 5.00 5.00
Fructooligosaccharides 5.00
Mineral & trace element premix  (AIN-93M-MX) 3.50 5.83
          [including 22% Sucrose] 0.77 1.28
Vitamin mix (AIN-93-VX) 1.00 1.67
          [Including 97% Sucrose] 0.97 1.62
Choline chloride  (50%; 0,434 g / g) 0.23 0.38
Tert-butylhydroquinone 0.0008 0.0013
Control New KD
mg / 100g diet mg / 100g diet
C-8:0 64.4 897.3
C-10:0 51.5 699.1
C-12:0 395.0 2066.6
C-14:0 154.6 1317.0
C-16:0 492.4 18064.5
C-18:0 136.1 2285.2
C-18:1w9 (OA) 1040.6 19313.1
C-18:2w6 (LA) 2180.8 5055.2
C-18:3w3 (ALA) 107.4 527.6
C-20:5w3 (EPA) 0.0 326.3
C-22:6w3 (DHA) 0.0 1430.4
A. Total Fats 5.0 57.0
B. Total Proteins 12.1 18.1
C. Total Carbohydratess 71.1 4.2
D. Total Sucrose from Vits & Mins 1.7 2.9
Ketogenic ratio [A/(B+C+D)] 1 : 17 2.3 : 1
Energy (kcal/100g diet) 377 626
Fatty acid compositions:
Vits, Mins, Additions:
Fibres:
Carbohydrates:
Proteins:
Fats:
Table 1.
Composition of the experimental diets; control (cont.) vs. the new ketogenic diet (KD) (g/100 g).
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Figure 1. 
Motor function assessments. mNSS (A) and Rotarod (B). (A). Line graph 
showing the dynamic changes in the total scoring in mNSS, starting on the 24 h 
after the injury and throughout 70 days. From 3 dpi and thereafter, the new-KD fed 
animals showed a significant improvement compared to the CCI-Control group 
(Two way ANOVA;***p < 0.0001, F (2, 28) = 247.8 followed by Tukey's multiple 
comparisons test *p<0.05 (3dpi) **p<0.01 (5dpi)** *p<0.001(7-70dpi)); the 
craniotomy group showed significant improvement from 1 dpi and nearly no 
deficits after 14 dpi (***p<0.001 compared to CCI-Control). (B). On 1-3 dpi, both 
CCI-KD and craniotomy mice showed marked improvement compared with the
CCI-Control mice. Graph of individual replicates with connected lines-represents
the means. (Two-Way ANOVA; p < 0.0001, F(2, 27) = 37.46; Tukey's multiple 
comparisons test: CCI- Control and CCI-KD or craniotomy on  dpi 1 (p<0.05, 
P<0.001 respectively) and on dpi 2-3 (P<0.001). n=10/group. 
Cognitive performance assessment with MWM. (C). A significant increase in the 
latency to the first entry into the platform-quadrant was seen in CCI-Control 
animals in the probe test compared to the craniotomy group, and this was markedly 
reduced in the new-KD-treated animals (One way ANOVA; p = 0.001, F(2, 29) = 
8.262; Tukey's multiple comparisons test  ***P<0.001). On the right-hand side, a 
representative illustration of the track of an animal from each group, from the 
release point into the water until its first entrance to the platform quadrant. 
n=10/group.  
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Figure 2  
ß-hydroxybutyrate plasma levels. (A). Higher levels of ß-hydroxybutyrate (ß-
HB) were seen 70 days post injury in the new-KD fed animals compared to injured 
animals fed with control diet; In the craniotomy group ß-HB levels were not 
detectable (Unpaired t-test; ***p < 0.0009, F(8, 2) = 5.709). n=10/group. 
Lesion size. (B). Graph showing a significant reduction in lesion size in CCI mice 
treated with the new-KD compared with CCI-Control vs. craniotomy mice, at 70 
days post-TBI (Unpaired t-test; p =0.01, F(5, 4) = 2.161; **p<0.01) and 
representative sections stained with H&E showing differences in lesion size. 
n=5/group. 
Oxidative stress. (C). Immunohistochemistry quantification of 8-OHG positive 
cells around the lesion border 70 days post-TBI (One-way ANOVA p<0.0001, F(3, 
15) = 227.8; Tukey's multiple comparisons test ***p <0.001), and representative 
images (a-c). n=5/group. 
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Figure 3. Lipid analysis. (A). Tissue PC and PE levels were reduced following the brain 
injury compared to craniotomy controls. This reduction was 12% (PC) or 8.5% (PE) lesser in 
the new KD group compared with craniotomy controls. Two-way ANOVA; lipid factor: 
***P<0.0001 F (1, 26) = 73.73 group factor ***P<0.0001 F (2, 26) = 43.53; Sidak's multiple 
comparisons test*p<0.05** p<0.01*** p <0.001). (B). Tissue PI, PS and SPH levels were 
decreased following the injury with no major differences between control and KD diet. Two-
way ANOVA; lipid factor: ***P<0.0001, F (2, 39) = 202.2, group factor ***P<0.0001F (2, 
39) = 15.12; Sidak's multiple comparisons test*p<0.05** p<0.01).
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Figure 4. Neuroinflammatory response 70 days post-TBI. 
Immunohistochemistry quantification around the lesion border, of (A) % Iba-1 
positive cells (One way ANOVA; p = 0.0026, F(2, 12) = 10.15; Tukey's multiple 
comparisons test *p<0.05 **p <0.01) and representative images (b,f,j). (B) TSPO 
positive cells (One way ANOVA; p < 0.0001, F(2, 12) = 119.3; Tukey's multiple 
comparisons test ***p <0.001) and representative images (c,g,k). (C) Co-localised 
TSPO and Iba-1 positive cells (One way ANOVA; p < 0.0001, F(2, 12) = 68.56; 
Tukey's multiple comparisons test ***p <0.001) and representative images (d,h,l). 
Note the different microglia morphology (activation): amoeboid vs. ramified. Scale 
bars=100 µm. To show co-localization we enlarged the area marked with a 
rectangle. Scale bars= 100 µm. (d) Microglia cell size analysis showing the 
differences in cell size (Mann Whitney test **p<0.01) and corresponding images. 
The insets show the clear morphological differences. Scale bars= 100 µm. 
n=5/group. 
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Figure 5. Astrocytic response 70 days post-injury. Immunohistochemistry 
quantification around the lesion border, of (A) % GFAP positive cells (One way 
ANOVA p < 0.0001, F(2, 10) = 118.8; Tukey's multiple comparisons test 
***p<0.001) and representative images (b,f,j). (B). % BrdU positive cells (One way 
ANOVA p < 0.0001, F(2, 12) = 23.71; Tukey's multiple comparisons test 
**p<0.01***p<0.001) and representative images (c,g,k). (C). Co-localised % 
GFAP and BrdU positive cells (One way ANOVA; p < 0.0001, F(2, 10) = 9.652; 
Tukey's multiple comparisons test *p<0.05 **p<0.01) and representative images 
(d,h,l). n=5/group.  
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Figure 6. Oligodendrocytes. (A). Quantification of oligodendrocytes 70 days post-
TBI (APC positive cells) (One way ANOVA p = 0.005, F(2, 12) = 8.563; Tukey's 
multiple comparisons test **p<0.01 ***p<0.001) and representative images (b,f,j).) 
(B). Dual staining APC and BrdU (One way ANOVA p = 0.0002, F(2, 12) = 18.15; 
Tukey's multiple comparisons test *p<0.05 **p<0.01) and representative images 
(d,h.l). Scale bar=100 µm. n=5/group. 
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Figure 7. mTOR pathway. Graph and representative cropped gels of western blot
analysis of protein levels of: (A). Phosphorylated mTOR (Ser2448) (289 kDa) (One 
way ANOVA p < 0.0001, F(2, 11) = 37.44; Tukey's multiple comparisons test **p< 
0.01***p<0.001), (B). Total mTOR; 289 kDa (One way ANOVA: ns F(2, 14) = 
0.5253; Tukey's multiple comparisons test: ns), and (C). Phosphorylated-mTOR/
total mTOR ratio. 
(D). Phosphorylated -p70S6K (Thr389); 70 kDa & 85 kDa ( One way ANOVA p = 
0.4188, F (2, 7) = 44.72; All measurements were assessed at 70 days post-TBI. 
Tukey's multiple comparisons test **p<0.01 ***p<0.001). Vinculin (117kDa) was 
used as loading control. 
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Figure 8. 
Complex-ɪ mitochondrial marker. (A). Quantification of NDUFS4 positive cells 
70 days post-TBI (One-way ANOVA p = 0.0006, F(2, 9) = 19.18; Tukey's multiple 
comparisons test  *p<0.05, **p<0.01 ***P<0.001).  
Epigenetics markers. Quantification of (B). H3K9 Methylation ratio (One-way 
ANOVA p =0.0004, F (3, 15) = 11.33; Tukey's multiple comparisons test **p 
<0.002) and (C). H3K9 Acetylation ratio (One-way ANOVA p <0.0001, F(3, 15) = 
20.71; Tukey's multiple comparisons test ***p <0.001).  
All measurements were assessed at 70 days post-TBI. n=5/group. 
Supplementary data 
Type Identifier KD ratio Fat Protein Carb kcal/100g Fibres n-3 PUFAs MCTs Reference
Teklad #7013 1:10 18 23 59 308 4% 0.30% 0% Appelberg 2009
AIN93M 1:12 16 18 66 391 5% 0.48% 0% Ma 2018
Purina 5001 1:15 14 29 58 334 5% 0.19% -- Elamin 2017
BioServ F5960 1:17 12 19 69 379 -- 0.04% -- Steijger 2013
Control 1:17 12 13 76 377 5% 0.11% 0.5% current study
BioServ F3666 6:1 93 5 2 724 5% 0.67% -- Appelberg 2009; Elamin 2017
TP-201450 6:1 93 5 2 734 -- -- -- Ma 2018
BioServ F5848 3:1 88 11 2 677 -- 0.56% -- Steijger 2013
New KD 2:1 84 12 5 626 10%a 2,28%b 3.7% current study
Macronutrients %en
Co
nt
ro
l
KD
Table S1: Overview of the current Control diet and New KD diet characteristics as compared to some of the 
previously reported Control and KD diets. KD ratio = (fat w/w) : ((protein w/w) + (carb w/w)). Carb = 
carbohydrates; MCTs = medium chain triglycerides; -- = unknown. a incl. 5% FOS. b incl. 1,76% DHA+EPA. Note 
that the current New KD has a low KD ratio, caused by a relatively low fat percentage and a relatively high carb 
percentage. It also has a high fibre content, with an additional 5% fructooligosaccharides (FOS) next to the usual 
5% of cellulose. The New KD contains the omega-3 polyunsaturated fatty acids (n-3 PUFAs) docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA). Finally, the New KD contains relatively high amounts of MCTs.
Appelberg KS, Hovda DA, Prins ML. The effects of a ketogenic diet on behavioral outcome after controlled 
cortical impact injury in the juvenile and adult rat. J Neurotrauma. 2009; 26: 497-506.
Elamin M, Ruskin DN, Masino SA, Sacchetti P. Ketone-Based Metabolic Therapy: Is Increased NAD(+) a Primary 
Mechanism? Front Mol Neurosci. 2017; 10: 377.
Ma S, Huang Q, Tominaga T, Liu C, Suzuki K. An 8-Week Ketogenic Diet Alternated Interleukin-6, Ketolytic and 
Lipolytic Gene Expression, and Enhanced Exercise Capacity in Mice. Nutrients. 2018; 10.
Streijger F, Plunet WT, Lee JH, Liu J, Lam CK, Park S, et al. Ketogenic diet improves forelimb motor function 
after spinal cord injury in rodents. PLoS One. 2013; 8: e78765.
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Figure S1. Body weights comparison and experimental design. 
A. Graphs of weekly measurements of group-weights average showing no 
differences between groups. 
B. Experimental design. The behavioural testing was performed for 70 days post-
injury (dpi). A controlled cortical impact (CCI) or a control craniotomy (sham injury) 
were induced in adult male mice. Animals were divided into 3 experimental groups 
(craniotomy-control, CCI-Control and CCI-KD). All mice were tested for motor and 
cognitive impairments. Mice were trained for three consecutive days for the 
Rotarod test prior to injury. Throughout the study (1-70 dpi), mice were tested for 
mNSS every other day on the first week and once a week thereafter, Rotarod (1-3 
dpi) and MWM (13-18 dpi). A week before the end of the study mice were injected 
twice a day with BrdU for the remaining time. Body weight were monitored daily. On 
70 dpi mice underwent perfusion for immunohistochemistry (IHC) analysis or were 
decapitated and brains were quickly removed and snap frozen for western blot 
(WB) analysis, lipid analysis and epigenetic marker measurements. 70 dpi plasma 
samples were collected and used for β-Hb quantification. 
Task Score
Exit - time* 1-3 
Walking straight 1
Startle reflex 1
Seeking behaviour 1
Hemiparesis 1
Round s�ck balance
1
Triangle s�ck 
balance 1
Beam walking**
1cm 1- 3
2cm 1- 3
3cm 1- 3
Total score 10 - 18
 *Exit task- points
0
1
2
3
0
Grasp side of the beam+  draging OR sliping poterior paw less than 3 1
2
3
no exit within 2 min
More than 3 �mes and no abili� to grip
Unable to walk the beam
**Beam walk-points
exit within 20 sec
exit within 60 sec
exit within 2 min
Balance and walk with normal  posture
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Figure S2. Modified neurological severity score test (mNSS), MWM-learning 
curve and Brain tissue process illustration. 
A. Content of the Modified Neurological severity scores (NSS) outlined in Table. This
modified test consists of 10 individual clinical parameters, including tasks on motor 
function, alertness and other neurophysiological indicators, to evaluate the 
neurological impairment. One point is awarded for the inability to perform the tasks. A 
maximal NSS of 18 points thus indicates severe neurological dysfunction, with failure 
on all tasks. Modifications of the scoring are represented with asterisks and detailed 
respectively in the second table. 
B. Morris water maze acquisition performance graph. Over the course of five
consecutive days, mice were given a series of four daily trials. Data are average of 
the latency (sec) to reach the goal (platform), using identical sequences of start 
locations. 
C. Dorsal view of a mouse brain illustrating the three sections that has been
processed; a. Ipsilateral hemisphere (right side), containing the injury/lesion, used 
for western blot analysis. b. Contralateral hemisphere (left side), used for H3 
Methylation/Acetylation Assay and c. Cerebellum, used for phospholipid analysis. 
